{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:41:37Z","timestamp":1766050897721,"version":"3.41.0"},"reference-count":34,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of General Medical Sciences of the National Institutes of Health","award":["P20GM103447"],"award-info":[{"award-number":["P20GM103447"]}]},{"name":"Faculty Research Committee of Northeastern State University","award":["24-01"],"award-info":[{"award-number":["24-01"]}]},{"name":"NIH","award":["GM116031"],"award-info":[{"award-number":["GM116031"]}]},{"name":"Welch Robert Foundation","award":["Z-0036"],"award-info":[{"award-number":["Z-0036"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Schol Ed)"],"abstract":"<jats:p>Background: Histone deacetylase 1 (HDAC1) is a critical epigenetic regulator involved in chromatin remodeling and transcriptional repression, making it a valuable target for cancer therapy. Selective inhibition of HDAC1 represents a promising approach to cancer treatment, as it modulates gene expression and induces apoptosis in tumor cells. Methods: Two novel hydroxamate-based HDAC1 inhibitors, compounds 4 and 6, were designed and evaluated using molecular docking, molecular dynamics (MD) simulations, and enzymatic inhibition assays. Molecular docking assessed binding interactions, while MD simulations evaluated the stability of the ligand\u2013protein complexes. Enzymatic inhibition assays were used to determine the IC50 values and evaluate the potency of the compounds. Results: Molecular docking revealed that both compounds exhibited significant interactions with HDAC1, including hydrophobic contacts, hydrogen bonding, and zinc coordination. Compound 4 demonstrated a stronger binding affinity (\u20136.2 kcal\/mol) compared to compound 6 (\u20135.7 kcal\/mol). The MD simulations confirmed that compound 4 exhibited greater stability, with divalent zinc coordination (4.3 \u00c5 and 4.8 \u00c5), whereas compound 6 showed weaker monovalent coordination (4.4 \u00c5). Enzymatic assays demonstrated that compound 4 had an IC50 of 2.96 \u00b1 0.4 \u03bcM, while compound 6 exhibited an IC50 of 4.76 \u00b1 0.5 \u03bcM; thus, compound 4 possesses superior inhibitory potency. Conclusions: Compound 4 exhibits enhanced binding affinity, stability, and enzymatic inhibition compared to compound 6, suggesting that this compound may serve as a promising lead for the development of selective HDAC1 inhibitors.<\/jats:p>","DOI":"10.31083\/fbs38998","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:31:53Z","timestamp":1751434313000},"source":"Crossref","is-referenced-by-count":2,"title":["Inhibitory Effect of Novel Dihydroxamate Derivatives for Histone Deacetylase 1"],"prefix":"10.31083","volume":"17","author":[{"given":"Jhawn G.","family":"Saul","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Microbiology at Oklahoma State University-Center for Health Sciences, College of Osteopathic Medicine, Tulsa, OK 74464, USA"},{"name":"Department of Physical Sciences, Northeastern State University, Broken Arrow, OK 74014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-8307","authenticated-orcid":true,"given":"Andrew E.","family":"Huckleby","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Microbiology at Oklahoma State University-Center for Health Sciences, College of Osteopathic Medicine, Tulsa, OK 74464, USA"},{"name":"Department of Physical Sciences, Northeastern State University, Broken Arrow, OK 74014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia C.","family":"Gugello","sequence":"first","affiliation":[{"name":"Department of Physical Sciences, Northeastern State University, Broken Arrow, OK 74014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-7143","authenticated-orcid":true,"given":"Jonathan","family":"Urbanczyk","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, McMurry University, Abilene, TX 79697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staci","family":"Desmarais","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, McMurry University, Abilene, TX 79697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7901-5341","authenticated-orcid":true,"given":"Hyunshun","family":"Shin","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, McMurry University, Abilene, TX 79697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3138-8178","authenticated-orcid":true,"given":"Apparao","family":"Bokka","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, The University of Texas, Arlington, TX 76019, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-8098","authenticated-orcid":true,"given":"Junha","family":"Jeon","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, The University of Texas, Arlington, TX 76019, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatindra N.","family":"Tripathy","sequence":"first","affiliation":[{"name":"Center for Biotechnology and Genomics, Texas Tech University, Lubbock, TX 79409, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2325-245X","authenticated-orcid":true,"given":"Sung-Kun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Physical Sciences, Northeastern State University, Broken Arrow, OK 74014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. The Biochemical Journal. 2003; 370: 737\u2013749.","DOI":"10.1042\/BJ20021321."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Blander G, Guarente L. The Sir2 family of protein deacetylases. Annual Review of Biochemistry. 2004; 73: 417\u2013435.","DOI":"10.1146\/annurev.biochem.73.011303.073651."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Kim S-K, Nightingale NL, Lee KK, Ferlazzo CM, Neff LE, Tripathy JN. Modulation of tumor suppressor genes by histone deacetylase inhibitors in cancer therapy. Journal of Pharmaceutical Research International. 2024; 36: 1\u201319.","DOI":"10.9734\/jpri\/2024\/v36i117596."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harbor Perspectives in Biology. 2014; 6: a018713.","DOI":"10.1101\/cshperspect.a018713."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gray SG, Ekstr\u00f6m TJ. The human histone deacetylase family. Experimental Cell Research. 2001; 262: 75\u201383.","DOI":"10.1006\/excr.2000.5080."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Dovey OM, Foster CT, Conte N, Edwards SA, Edwards JM, Singh R, et al. Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood. 2013; 121: 1335\u20131344.","DOI":"10.1182\/blood-2012-07-441949."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Heideman MR, Wilting RH, Yanover E, Velds A, de Jong J, Kerkhoven RM, et al. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood. 2013; 121: 2038\u20132050.","DOI":"10.1182\/blood-2012-08-450916."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Santoro F, Botrugno OA, Dal Zuffo R, Pallavicini I, Matthews GM, Cluse L, et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood. 2013; 121: 3459\u20133468.","DOI":"10.1182\/blood-2012-10-461988."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Draney\u202f C, Austin \u202fMC, Leifer\u202f AH, Smith\u202f CJ, Kener\u202f KB, Aitken\u202f TJ, et al. HDAC1 overexpression enhances \u03b2-cell proliferation by down-regulating Cdkn1b\/p27. The Biochemical Journal. 2018; 475: 3997\u20134010.","DOI":"10.1042\/BCJ20180465."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 1998; 391: 597\u2013601.","DOI":"10.1038\/35404."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Wright CA, Gordon ER, Cooper SJ. Genomic analysis reveals HDAC1 regulates clinically relevant transcriptional programs in Pancreatic cancer. BMC Cancer. 2023; 23: 1137.","DOI":"10.1186\/s12885-023-11645-0."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. Journal of Medicinal Chemistry. 2003; 46: 5097\u20135116.","DOI":"10.1021\/jm0303094."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology. 2005; 45: 495\u2013528.","DOI":"10.1146\/annurev.pharmtox.45.120403.095825."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Liu WB, Song J, Zhang SY. A short overview of dual targeting HDAC inhibitors. Future Medicinal Chemistry. 2024; 17: 5\u20137.","DOI":"10.1080\/17568919.2024.2437975."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Cheng B, Pan W, Xiao Y, Ding Z, Zhou Y, Fei X, et al. HDAC-targeting epigenetic modulators for cancer immunotherapy. European Journal of Medicinal Chemistry. 2024; 265: 116129.","DOI":"10.1016\/j.ejmech.2024.116129."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999; 401: 188\u2013193.","DOI":"10.1038\/43710."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Zong X, Yang Z, Zhou J, Jin Z, Wu D. Clinical trial: Chidamide plus CHOP improve the survival of newly diagnosed angioimmunoblastic T-cell lymphoma. Frontiers in Immunology. 2024; 15: 1430648.","DOI":"10.3389\/fimmu.2024.1430648."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Chou CJ, Herman D, Gottesfeld JM. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. The Journal of Biological Chemistry. 2008; 283: 35402\u201335409.","DOI":"10.1074\/jbc.M807045200."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978; 14: 105\u2013113.","DOI":"10.1016\/0092-8674(78)90305-7."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. The Journal of Clinical Investigation. 2014; 124: 30\u201339.","DOI":"10.1172\/JCI69738."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Li Y, Seto \u202fE. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harbor Perspectives in Medicine. 2016; 6: a026831.","DOI":"10.1101\/cshperspect.a026831."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Chen X, Sun K, Jiao S, Cai N, Zhao X, Zou H, et al. High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients. Scientific Reports. 2014; 4: 7481.","DOI":"10.1038\/srep07481."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Walkinshaw\u202f DR, Yang \u202fXJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Current Oncology. 2008; 15: 237\u2013243.","DOI":"10.3747\/co.v15i5.371."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Duan N, Hu X, Qiu H, Zhou R, Li Y, Lu W, et al. Targeting the E2F1\/Rb\/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth. Cell Death & Disease. 2023; 14: 801.","DOI":"10.1038\/s41419-023-06205-0."},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein & Cell. 2020; 11:472\u2013482.","DOI":"10.1007\/s13238-020-00694-x."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology. 2007; 25: 84\u201390.","DOI":"10.1038\/nbt1272."},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Groselj\u202f B, Sharma\u202f NL, Hamdy\u202f FC, Kerr\u202f M, Kiltie\u202f AE. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. British Journal of Cancer. 2013; 108: 748\u2013754.","DOI":"10.1038\/bjc.2013.21."},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews. Cancer. 2006; 6: 38\u201351.","DOI":"10.1038\/nrc1779."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. Journal of Cheminformatics. 2012; 4: 17.","DOI":"10.1186\/1758-2946-4-17."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 2010; 31: 455\u2013461.","DOI":"10.1002\/jcc.21334."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, et al. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Research. 2021; 49: W530\u2013W534.","DOI":"10.1093\/nar\/gkab294."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Macchiagodena M, Pagliai M, Andreini C, Rosato A, Procacci P. Upgrading and Validation of the AMBER Force Field for Histidine and Cysteine Zinc(II)-Binding Residues in Sites with Four Protein Ligands. Journal of Chemical Information and Modeling. 2019; 59: 3803\u20133816.","DOI":"10.1021\/acs.jcim.9b00407."},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Macchiagodena M, Pagliai M, Andreini C, Rosato A, Procacci P. Upgraded AMBER Force Field for Zinc-Binding Residues and Ligands for Predicting Structural Properties and Binding Affinities in Zinc-Proteins. ACS Omega. 2020; 5: 15301\u201315310.","DOI":"10.1021\/acsomega.0c01337."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Sousa da Silva AW, Vranken WF. ACPYPE - AnteChamber PYthon Parser interfacE. BMC Research Notes. 2012; 5: 367.","DOI":"10.1186\/1756-0500-5-367."}],"container-title":["Frontiers in Bioscience-Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/17\/2\/10.31083\/FBS38998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:32:04Z","timestamp":1751434324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBS\/17\/2\/10.31083\/FBS38998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"alternative-id":["S1945-0516(25)00139-X"],"URL":"https:\/\/doi.org\/10.31083\/fbs38998","relation":{},"ISSN":["1945-0516","1945-0524"],"issn-type":[{"value":"1945-0516","type":"print"},{"value":"1945-0524","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}